Milestone Pharmaceuticals is dedicated to providing a sense of security and peace of mind to patients with paroxysmal supraventricular tachycardia (PSVT) and other episodic cardiovascular conditions. With a focus on developing innovative therapies for self-administration outside of the hospital setting, Milestone aims to fill the existing gap in treatment options for these patients. Their investigational product, etripamil, is a nasal spray that delivers a novel calcium channel blocker.

It is designed for the acute at-home treatment of PSVT, atrial fibrillation with rapid ventricular rate (AFib-RVR), and other episodic cardiovascular conditions. With Milestone Pharmaceuticals' therapies, patients can have access to rapid termination of their symptoms wherever they may be when they occur. Milestone is dedicated to advancing scientific discovery through clinical trials, and they express their gratitude to patient volunteers and healthcare researchers, as their collaboration is crucial in achieving medical progress.

For patients seeking cardiac peace of mind, Milestone Pharmaceuticals is there to support them every step of the way